Key Takeaways

An experimental GLP-1 pill promotes weight loss, clinical trial results show

Orforglipron caused up to 11% body weight loss during a year and a half

The pill also outperformed a tablet form of semaglutide in a head-to-head trial

FRIDAY, Sept. 19, 2025 (HealthDay News) — An effective weight-loss pill to rival injectable drugs like Ozempic and Zepbound might be on the horizon, clinical trial results show.

An experimental GLP-1 pill called orforglipron promoted substantial weight loss without the need for weekly injections, according to final clinical trial results published Sept. 16 in The New England Journal of Medicine .

Orforglipron also outperformed a tablet form of semaglutide that’s already on the market, in both driving weight loss and controlling blood sugar,

See Full Page